A Double Blind Placebo Controlled Study of Valaciclovir in Treatment of Psychosis in Patients With Schizophrenia.

Trial Profile

A Double Blind Placebo Controlled Study of Valaciclovir in Treatment of Psychosis in Patients With Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Valaciclovir (Primary)
  • Indications Psychotic disorders; Schizophrenia
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 30 Nov 2016 Status changed from recruiting to completed.
    • 17 Feb 2015 Planned End Date changed from 1 Jul 2013 to 1 Jan 2016 as reported by ClinicalTrials.gov.
    • 17 Feb 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top